Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con ...
Although desmoid tumors do not metastasize, they can be associated with recurrence rates of up to 77% after surgical ...
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony ...
Merck officially opened its €150m filtration manufacturing facility at Blarney Business Park in Cork last month. The Blarney facility is part of Merck’s largest life science investment to date in ...
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutionsJSR’s ...
JSR Corp. (Tokyo) announced that it entered into an agreement to transfer its bioprocess materials business to Merck KGaA, Darmstadt, Germany, subject to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback